Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets

Published on Apr 1, 2020in Pathology3.744
· DOI :10.1016/J.PATHOL.2019.11.006
Anna Caliò (University of Verona), Anna Caliò16
Estimated H-index: 16
(University of Verona)
+ 19 AuthorsGuido Martignoni75
Estimated H-index: 75
(University of Verona)
Sources
Abstract
Summary Recently cabozantinib, a tyrosine kinase inhibitor with activity against VEGF, MET, AXL, and downregulating cathepsin K in vitro, has been proposed for the treatment of advanced clear and non-clear renal cell carcinomas. Since it is well known that cathepsin K is expressed in the majority of MiT family translocation renal cell carcinomas, we investigated cathepsin K, MET, AXL, and VEGF in a large series of those tumours, looking for possible predictive markers. We collected the clinicopathological features of 34 genetically confirmed MiT family translocation renal cell carcinomas [26 Xp11 and 8 t(6;11) renal cell carcinomas] and studied them using an immunohistochemical panel including PAX8, cathepsin K, HMB45, Melan-A, CD68 (PG-M1), CK7, CA9, MET, AXL and by FISH for VEGFA and MET. Cathepsin K was expressed in 14 of 26, HMB45 in 8 of 25, and Melan-A in 4 of 23 Xp11 renal cell carcinomas, whereas labelling for CK7 and CA9 was minimal. In t(6;11) renal cell carcinoma, cathepsin K and melanogenesis markers were constantly positive, whereas CK7 and CA9 were negative. None of the 34 carcinomas showed CD68 (PG-M1) and AXL expression. One aggressive Xp11 renal cell carcinoma showed increased VEGFA gene copy number (4–5 copies) with concurrent gains of TFE3 and TFEB. None of the 34 carcinomas showed MET gene amplification, whereas staining for MET was found in 7 of 8 t(6;11) and in 16 of 24 Xp11 renal cell carcinomas, and in the latter cases, when the expression was >50%, correlated with aggressiveness (p=0.0049). In Xp11 renal cell carcinomas, the aggressiveness was also correlated with larger tumour size (p=0.0008) and the presence of necrosis (p=0.027) but not nucleolar grading (p=1). Interestingly, in patients with tumours exhibiting two of three parameters (necrosis, larger tumour size and MET immunolabelling >50%) an aggressive clinical behaviour was observed in 88% of cases. In conclusion, cathepsin K, CD68 (PG-M1), CK7, CA9, and PAX8 is a useful panel for the diagnosis. Larger tumour size, the presence of necrosis and MET immunohistochemical expression correlate with aggressive behaviour in Xp11 renal cell carcinomas, especially in combination. VEGF, MET, cathepsin K but not AXL may be potential predictive markers for targeted therapy in MiT family translocation renal cell carcinomas.
📖 Papers frequently viewed together
12 Citations
19 Citations
5 Citations
References45
Newest
#1Anna Caliò (University of Verona)H-Index: 16
#2Diego SegalaH-Index: 14
Last. Guido Martignoni (University of Verona)H-Index: 75
view all 5 authors...
The new category of MiT family translocation renal cell carcinoma has been included into the World Health Organization (WHO) classification in 2016. The MiT family translocation renal cell carcinoma comprises Xp11 translocation renal cell carcinoma harboring TFE3 gene fusions and t(6;11) renal cell carcinoma harboring TFEB gene fusion. At the beginning, they were recognized in childhood; nevertheless, it has been demonstrated that these neoplasms can occur in adults as well. In the nineties, amo...
23 CitationsSource
#1Nieves Martinez Chanza (Harvard University)H-Index: 7
#2Wanling Xie (Harvard University)H-Index: 51
Last. Lauren C. Harshman (Harvard University)H-Index: 27
view all 38 authors...
Summary Background Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised. We sought to analyse the antitumour activity and toxicity of cabozantinib in advanced non-clear-cell renal cell carcinoma. Methods We did a multicentre, international, retrospective cohort study of patients with metastatic non-clear-cell renal c...
46 CitationsSource
#1Anna Caliò (University of Verona)H-Index: 16
#2Matteo Brunelli (University of Verona)H-Index: 46
Last. Guido Martignoni (University of Verona)H-Index: 75
view all 7 authors...
Amplification of vascular endothelial growth factor A (VEGFA) has been recently reported in TFEB-amplified renal cell carcinomas regardless the level of TFEB amplification. We sought to determine VEGFA amplification by fluorescent in situ hybridization (FISH) and VEGFA mRNA expression by in situ hybridization (RNAscope 2.5) in a series of 10 renal cell carcinomas with TFEB gene alterations, either amplification and/or rearrangement (t(6;11) renal cell carcinoma). TFEB gene rearrangement was demo...
8 CitationsSource
#1Jianming Pei (Fox Chase Cancer Center)H-Index: 21
#2Harry S. Cooper (Fox Chase Cancer Center)H-Index: 50
Last. Shuanzeng Wei (Fox Chase Cancer Center)H-Index: 4
view all 10 authors...
Microphthalmia-associated transcription factor (MiT) family translocation renal cell carcinoma harbors variable gene fusions involving either TFE3 or TFEB genes. Multiple 5′ fusion partners for TFE3 have been reported, including ASPSCR1, CLTC, DVL2, LUC7L3, KHSRP, PRCC, PARP14, NONO, SFPQ1, MED15, and RBM10. Each of these fusion genes activates TFE3 transcription which can be detected by immunostaining. Using targeted RNA-sequencing, TFE3 fusion gene partners were identified in 5 cases of TFE3 i...
25 CitationsSource
#1Nur P. Damayanti (IU: Indiana University)H-Index: 11
#2Justin A. Budka (IU: Indiana University)H-Index: 7
Last. Roberto Pili (IU: Indiana University)H-Index: 69
view all 18 authors...
Purpose: Translocation renal cell carcinoma (tRCC) represents a rare subtype of kidney cancer associated with various TFE3, TFEB, or MITF gene fusions that are not responsive to standard treatments for RCC. Therefore, the identification of new therapeutic targets represents an unmet need for this disease. Experimental design: We have established and characterized a tRCC patient-derived xenograft, RP-R07, as a novel preclinical model for drug development by using next-generation sequencing and bi...
26 CitationsSource
#1Anna Caliò (University of Verona)H-Index: 16
#2Matteo Brunelli (University of Verona)H-Index: 46
Last. Guido Martignoni (University of Verona)H-Index: 75
view all 13 authors...
t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma
19 CitationsSource
#1Stephanie L. Skala (UM: University of Michigan)H-Index: 9
#2Hong Xiao (UM: University of Michigan)H-Index: 8
Last. Rohit Mehra (UM: University of Michigan)H-Index: 71
view all 22 authors...
Detection of 6 TFEB -amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays
32 CitationsSource
#1Sean R. Williamson (HFHS: Henry Ford Health System)H-Index: 30
#2David J. Grignon (IU: Indiana University)H-Index: 32
Last. Liang Cheng (IU: Indiana University)H-Index: 132
view all 6 authors...
Reply to Chou et al ‘Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution’ Mod Pathol 2017; in press.
3 CitationsSource
#1Angela Chou (Kolling Institute of Medical Research)H-Index: 25
#2Ondrej Hes (Charles University in Prague)H-Index: 36
Last. Anthony J. Gill (Kolling Institute of Medical Research)H-Index: 73
view all 5 authors...
Do significant TFE3 gene rearrangements occur in succinate dehydrogenase-deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution
5 CitationsSource
#1Marion ClasseH-Index: 7
#2Gabriel G. MaloufH-Index: 26
Last. Xavier LeroyH-Index: 23
view all 14 authors...
Aims Translocation renal cell carcinoma (tRCC) is a rare subtype of kidney tumour characterized by translocations involving the transcription factor TFE3 or TFEB. tRCC was introduced into the World Health Organization classification in 2004, but much is still unknown about the natural history, clinicopathologic features, and outcomes of the disease. The aim of this study was to describe the landscape of fusion transcript in a large single-institution series of FISH confirmed tRCCs and then to co...
33 CitationsSource
Cited By8
Newest
#1Daniel Abensur Athanazio (UFBA: Federal University of Bahia)H-Index: 15
Last. Stephania M. BezerraH-Index: 15
view all 10 authors...
Classification of renal cell carcinomas has become more challenging. The 2016 WHO classification included 14 different subtypes and 4 emerging/provisional entities, and recent literature indicates new entities to be incorporated. Nomenclature is based on cytoplasmic appearance, architecture, combination of morphologies, anatomic location, underlying disease, familial syndromes, and specific genetic alterations. Immunohistochemistry is useful in selected cases while it can be insufficient in enti...
Source
#1Shuko Harada (UAB: University of Alabama at Birmingham)H-Index: 19
#2Anna Caliò (University of Verona)H-Index: 16
Last. George J. Netto (UAB: University of Alabama at Birmingham)H-Index: 79
view all 0 authors...
MiT family translocation renal cell carcinoma (MiT-RCC) harbors translocations involving the TFE3 or TFEB genes. RCC with TFEB amplification is also identified and is associated with a more aggressive clinical course. Accurate diagnosis of MiT-RCC is crucial for patient management. In this study, we evaluated the performance of the Archer FusionPlex assay for detection of MiT-RCC with TFE3 or TFEB translocations and TFEB amplifications. RNA was extracted from 49 RCC FFPE tissue samples with know...
Source
#1Alexander S. Taylor (UM: University of Michigan)H-Index: 4
#2Stephanie L. Skala (UM: University of Michigan)H-Index: 9
Although papillary renal cell carcinoma has historically been classified as either type 1 or type 2, data from The Cancer Genome Atlas (TCGA) has demonstrated significant genomic heterogeneity in tumors classified as "type 2 papillary renal cell carcinoma" (T2PRCC). Papillary renal cell carcinoma is expected to have a favorable clinical course compared to clear cell renal cell carcinoma (CCRCC). However, tumors with poor outcome more similar to CCRCC were included in the T2PRCC cohort studied by...
Source
#1Anna CaliòH-Index: 16
#2Matteo BrunelliH-Index: 46
Last. Guido MartignoniH-Index: 75
view all 7 authors...
Cathepsin K is a papain-like cysteine protease with high matrix-degrading activity. Among several cathepsins, cathepsin K is the most potent mammalian collagenase, mainly expressed by osteoclasts. This review summarizes most of the recent findings of cathepsin K expression, highlighting its role in renal tumors for diagnostic purposes and as a potential molecular target. Indeed, cathepsin K is a recognized diagnostic tool for the identification of TFE3/TFEB-rearranged renal cell carcinoma, TFEB-...
Source
#1Jaclyn M Plotzke (UM: University of Michigan)
#2Raymond Zhao (UM: University of Michigan)H-Index: 2
Last. May P. Chan (UM: University of Michigan)H-Index: 15
view all 6 authors...
BACKGROUND Deviations from the classic melanocytic immunophenotype in melanoma can present a diagnostic challenge. PAX8 and PAX2 are common markers for renal or Mullerian differentiation. While most PAX8+ or PAX2+ carcinomas are seldom confused with melanoma, some cases may show a more ambiguous immunophenotype, especially when MiTF family altered renal cell carcinoma (MiTF-RCC) is in the differential diagnosis. Neither PAX8 nor PAX2 expression has been reported in melanoma to date. We aimed to ...
Source
#1Anna Caliò (University of Verona)H-Index: 16
#2Shuko Harada (UAB: University of Alabama at Birmingham)H-Index: 19
Last. Guido Martignoni (University of Verona)H-Index: 75
view all 10 authors...
Renal cell carcinomas with t(6;11) chromosome translocation has been classically characterized by the rearrangement of the TFEB gene, located on chromosome 6, and MALAT1 gene, located on chromosome 11. Recently, a few other genes have been described as fusion partners in TFEB rearranged renal cell carcinomas. Although most of TFEB rearranged renal cell carcinomas have an indolent behavior, in the rare cases of advanced metastatic disease targeted therapy and predictive markers remain lacking. In...
Source
#1Anna Caliò (University of Verona)H-Index: 16
#2Serena Ammendola (University of Verona)H-Index: 3
Last. Guido Martignoni (University of Verona)H-Index: 75
view all 6 authors...
Parvalbumin is a cytosolic calcium-binding protein expressed in the distal convoluted tubule of the renal nephron. Among epithelial renal tumors, the reactivity for parvalbumin is observed in chromophobe renal cell carcinomas and frequently in oncocytomas. On the other hand, there are no data available on parvalbumin expression in the mesenchymal tumors of the kidney. Therefore, the purpose of this study was to evaluate the expression of parvalbumin in the spectrum of PEC (perivascular epithelio...
2 CitationsSource
#1Yuqing WuH-Index: 3
#2Saisai ChenH-Index: 1
Last. Ming Chen (SEU: Southeast University)H-Index: 18
view all 10 authors...
Source
#1Mahmut Akgul (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 3
#2Liang Cheng (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 132
Last. Muhammad T. Idrees (IUPUI: Indiana University – Purdue University Indianapolis)H-Index: 3
view all 3 authors...
Source
#1Mahmut Akgul (Albany Medical College)
#1Mahmut Akgul (Albany Medical College)H-Index: 2
Last. Muhammad T. Idrees (IU: Indiana University)H-Index: 19
view all 50 authors...
Transcription factor E3-rearranged renal cell carcinoma (TFE3-RCC) has heterogenous morphologic and immunohistochemical (IHC) features.131 pathologists with genitourinary expertise were invited in an online survey containing 23 questions assessing their experience on TFE3-RCC diagnostic work-up.Fifty (38%) participants completed the survey. 46 of 50 participants reported multiple patterns, most commonly papillary pattern (almost always 9/46, 19.5%; frequently 29/46, 63%). Large epithelioid cells...
Source